OCTUMI-4: Evaluation of Mirtazapine and Folic Acid for Schizophrenia: A Large Simple 2x2 Factorial Trial.

Trial Profile

OCTUMI-4: Evaluation of Mirtazapine and Folic Acid for Schizophrenia: A Large Simple 2x2 Factorial Trial.

Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Jun 2015

At a glance

  • Drugs Folic acid (Primary) ; Mirtazapine (Primary)
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Acronyms OCTUMI-4; RECOVERY
  • Most Recent Events

    • 14 Nov 2013 Accrual to date is 17% according to United Kingdom Clinical Research Network.
    • 17 Jul 2013 Accrual to date is 21% according to United Kingdom Clinical Research Network.
    • 16 Jun 2013 Accrual to date is 19% according to United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top